| アブストラクト | BACKGROUND: Blocking muscarinic receptors could have an effect on cardiac function, especially among elderly patients with overactive bladder (OAB). STUDY OBJECTIVE: To investigate the risk of cardiovascular (CV) events in users of antimuscarinic drugs to treat OAB. DESIGN, SETTING, AND PARTICIPANTS: Cohort study of new users of darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, or trospium, 18 years or older, in the United Kingdom's Clinical Practice Research Datalink (CPRD), 2004-2012. OUTCOME MEASUREMENTS AND MAIN RESULTS: Using tolterodine as the reference, we estimated propensity-score-stratified incidence rate ratios (IRRs) for acute myocardial infarction, stroke, CV mortality, major adverse cardiac events (MACE, a combined end point of the previous three), and all-cause death for individual antimuscarinic drugs. The study cohort included 119,912 new users of OAB drugs. The mean age at cohort entry was 62 years, 70% were female, and the mean follow-up was 3.3 years. The adjusted IRR for MACE and current use of oxybutynin compared with current use of tolterodine was 1.14 (95% confidence interval [CI] 1.01-1.30). In contrast, the IRR was 0.65 (CI 0.56-0.76) for current use of solifenacin compared with tolterodine. In this study, performed with health care data, the distribution of risk factors was relatively similar across users of different OAB drugs and, although our analyses controlled for a range of measured potential confounders, residual confounding cannot be ruled out. CONCLUSIONS: In an observational comparative study of users of medications to treat OAB conducted in routine clinical practice, the risk for CV side effects was increased in users of oxybutynin and decreased in users of solifenacin compared with users of tolterodine. |
|---|
| 投稿者 | Arana, Alejandro; Margulis, Andrea V; McQuay, Lisa J; Ziemiecki, Ryan; Bartsch, Jennifer L; Rothman, Kenneth J; Franks, Billy; D'Silva, Milbhor; Appenteng, Kwame; Varas-Lorenzo, Cristina; Perez-Gutthann, Susana |
|---|
| 組織名 | RTI Health Solutions, Barcelona, Spain.;RTI Health Solutions, Research Triangle Park, North Carolina.;RTI Health Solutions, Waltham, Massachusetts.;Astellas Pharma B.V., Leiden, The Netherlands.;Astellas Pharma Global Development Inc., Northbrook, Illinois. |
|---|
